Organovo, Inc.

128 articles about Organovo, Inc.

• Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

  4/15/2024

  Organovo Holdings, Inc. today released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH).

• Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

  12/6/2023

  Organovo Holdings, Inc. today announced that it will release final and complete data from a Phase 2a trial of FXR314 in non-alcoholic steatohepatitis (NASH) patients by April 2024.

• Organovo Highlights FXR314 Combination Therapy Potential and Plan

  11/8/2023

  Organovo Holdings, Inc. announced its intention to study combination therapy in inflammatory bowel disease and release data in calendar Q3 2024.

• Organovo Announces Postponement of Annual Meeting of Stockholders - September 06, 2022

  9/6/2022

  Organovo Holdings, Inc., an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease, announced that its 2022 Annual Meeting of Stockholders that was scheduled to be held at 9:00AM on Wednesday, September 7, 2022 has been postponed to October 12, 2022 at 9:00AM, a date determined by the Company’s board of directors.

• Organovo Achieves 3D Tissue Model for Crohn’s Disease

  5/17/2022

  Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announces that it has successfully advanced its first inflammatory bowel disease (IBD) model to the next step of target discovery and validation for Crohn’s disease.  

• UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

  3/1/2022

  Organovo Holdings, Inc., and BICO announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting.

• Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

  2/23/2022

  Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting.

• Organovo Welcomes New Sr. Vice President of Strategy and Business Development

  2/18/2022

  Organovo Holdings, Inc., a three-dimensional biology company focused on delivering scientific and medical breakthroughs using 3D bioprinting technology, announced the hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development.

• Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Feb 18, 2022

  2/18/2022

  Organovo Holdings, Inc., announced that it has granted a stock option to purchase 50,000 shares of common stock to one new employee.

• Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents

  2/2/2022

  Organovo Holdings, Inc., announced that two of its patents have withstood a patent challenge, and the company provided guidance on how it expects to leverage its strong patent portfolio.

• Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022

  11/30/2021

  Organovo Holdings, Inc., provided a business overview and progress update, and announced it is on track to establish its first models of inflammatory bowel disease in 2022 using its 3D bioprinting and other 3D tissue technologies.

• Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

  9/17/2021

  Organovo Holdings, Inc., announced that the Company’s annual meeting of shareholders, on September 14, 2021, at 9:00 a.m. was convened and adjourned, without any business being conducted, due to lack of the required quorum.

• Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE)

  3/2/2021

  Organovo Holdings, Inc. (Nasdaq: ONVO), today announced it will be featured as a presenting company at the H.C. Wainwright Global Life Sciences Conference. The conference is being held on March 9-10, 2021 virtually. Keith Murphy, Executive Chairman of Organovo, will provide an overview of the Company's business during the presentation. A webcast of Organovo’s presentation will be accessible through the Investors & Media section of

• Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

  9/3/2020

  Organovo Holdings, Inc. (“Organovo” or the “Company”) (Nasdaq: ONVO) announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market (the “ Minimum Bid Price Requirement ”).  On September 2, 2020, Organovo received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, Inc. stating that because Organovo’s common stock had a closing bid price at or a

• Organovo Announces One-for-Twenty Reverse Stock Split

  8/17/2020

  Organovo Holdings, Inc. (the “Company”) (Nasdaq: ONVO) today announced that it filed a certificate of second amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The shares underlying the Company’s outstanding options and restricted stock unit awards will also be adjusted accordingly. The reverse stock split will take effect at 5:00 pm (Easter

• Organovo Holdings Founder Calls on Board of Directors to Accept Stockholders’ Opposition to the Illogical Merger With Tarveda Therapeutics

  4/2/2020

  Believes Stockholders Sent a Loud and Clear Message at Special Meeting That They Oppose This Value-Destructive Combination

• Organovo Holdings, Inc. Reminds Stockholders About Adjourned Special Meeting of Stockholders

  3/31/2020

  Organovo Holdings, Inc. convened, on March 26, 2020, the special meeting of stockholders and then adjourned the Special Meeting until Tuesday, April 7, 2020 10:00 A.M. Pacific Time at www.virtualshareholdermeeting.com/ONVO2020 to solicit additional proxies for Organovo Proposals Nos. 1 and 4.

• Organovo Holdings, Inc. Announces Adjournment of Special Meeting of Stockholders

  3/27/2020

  Organovo Holdings, Inc. convened, on March 26, 2020, the special meeting of stockholders and then adjourned the special meeting of stockholders until Tuesday, April 7, 2020 10:00 A.M. Pacific Time at www.virtualshareholdermeeting.com/ONVO2020 to solicit additional proxies for Organovo Proposal Nos. 1 and 4.

• Organovo Holdings Founder Issues Letter Regarding Alternative Paths to Illogical Merger With Tarveda Therapeutics to Stockholders

  3/23/2020

  Believes the Board, Which Has Presided Over Significant Value Destruction in Recent Years, Has Asked Stockholders to Take an Unnecessary Risk Without Offering a Compelling Rationale

• Organovo Files Definitive Proxy Statement and Sends Letter to Stockholders

  2/26/2020

  Feb. 26, 2020 13:30 UTC Recommends Stockholders Vote "FOR" Proposed Merger with Tarveda SAN DIEGO--( BUSINESS WIRE )-- Organovo Holdings, Inc. (“Organovo”) (NASDAQ: ONVO) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission and has mailed these materials and a letter to its stockholders in connection with the company’s Special Meeting to be held on March 26, 2020. Stockholders of record as of February 14, 2020 will be